

Introduction

More than 500 million people worldwide suffer from respiratory allergies. Many of them suffer in silence unnecessarily without clear avenues for support and treatment, choosing to self-medicate through over-the-counter medication. However, this method can negatively impact people's quality of life, healthcare systems and global economic development through lost productivity and workdays. ALK wishes to improve access to clinically proven allergy diagnosis and treatment solutions, ultimately improving the lives of allergy sufferers in the long term.

Statement of policy

The purpose of this policy is to set forth the respective principles related to ALK's Access to Medicines position and to provide information and guidance on managing the Access to Medicines strategy for the entire ALK Group.

Access to Allergy Care

ALK facilitates Access to Medicines through our Access to Allergy Care initiatives and principles. ALK's goal is to disseminate these solutions to more people, earlier in their disease journey. In order to fulfil this purpose, ALK builds on decades of research and development, and apply state-of-the-art pharmaceutical standards to deliver products and services to millions in need. However, millions more still lack access to modern medical care for their allergies and related asthma.

ALK applies three principles to enable Access to Allergy Care:

1. Improve quality of life through better allergy treatment options and earlier diagnosis

ALK helps to overcome barriers to access by continuing efforts in driving solid,

evidence-based research and development of state-of-the art pharmaceutical products, including maintaining their applicability across genders, ages and ethnicities. In addition, ALK is focused on servicing young people with allergies by progressing our approvals for children and adolescents to ensure diagnosis and treatment much earlier in life.

2. Support healthcare systems through training and education on allergy care

ALK plays a vital role in strengthening healthcare systems to ensure safe, effective and quality medicines for people with allergies. Through its expertise and capacity, ALK helps strengthen local healthcare systems through systematic training and educational activities for healthcare professionals, providing insights into allergy diagnosis and treatment innovations. ALK's responsibility extends to awareness raising activities, training and education efforts of both healthcare professionals and people challenged by allergies.

3. Partnerships for wider reach and access to allergy care

To increase the accessibility to allergy care, partnerships are crucial for ALK solutions to reach areas where immunotherapy treatments are not available. Therefore, ALK continues to develop new business partnership models with the aim to expand access to allergy care to an increasing number of countries and patients for a wider reach.

Measuring impact

In line with our three Access to Allergy Care principles, ALK has integrated a strategic ambition to reach more than 5 million patients by 2030 in its Allergy+ strategy.

Communication and reporting

ALK reports its progress towards reaching more patients internally and externally to stakeholders through its website, annual report.

Governance and responsibility

The oversight, accountability and responsibility for the strategy rests with ALK's Board of Directors, who have delegated this responsibility to the Executive Leadership Team.

Relevant business units across ALK are responsible for the daily management of the Allergy+ strategy.

Responsible business practices

ALK is committed to enabling access to more people with allergy, while ensuring that ALK continues to be a sustainable business. ALK practices business responsibly by adhering to all relevant laws, industry codes and guidelines¹, including but not limited to:

- Interactions with healthcare professionals, patient organisations, and the general public
- Conducting clinical trials and post-marketing activities
- Combatting corruption and anti-competitive behaviour (IP and non-IP-related)
- Promotion and marketing of treatment and services

ALK's Access to Medicines policy and strategy is reviewed continually by the Executive Leadership Team to ensure alignment with the overall strategy of the ALK group. The current version of this policy was considered and approved by the Executive Leadership Team in January 2025.

¹ The European Federation of Pharmaceutical Industries and Associations' (EFPIA's), the International Federation of Pharmaceutical Manufacturers & Associations' (IFPMA's) Codes of

Practice, as well as relevant codes and guidelines by the Pharmaceutical Research and Manufacturers of America (PhRMA).